Home
Search
Study Topics
Glossary
|
|
|
|
|
Tracking Information | |||||
---|---|---|---|---|---|
First Received Date † | July 26, 2002 | ||||
Last Updated Date | March 4, 2009 | ||||
Start Date † | March 2003 | ||||
Current Primary Outcome Measures † |
Area under the curve (AUC) [ Time Frame: throughout study ] [ Designated as safety issue: No ] | ||||
Original Primary Outcome Measures † | Same as current | ||||
Change History | Complete list of historical versions of study NCT00042289 on ClinicalTrials.gov Archive Site | ||||
Current Secondary Outcome Measures † |
|
||||
Original Secondary Outcome Measures † |
|
||||
Descriptive Information | |||||
Brief Title † | Pharmacokinetic Study of Anti-HIV Drugs During Pregnancy | ||||
Official Title † | Pharmacokinetic Properties of Antiretroviral Drugs During Pregnancy | ||||
Brief Summary | The purpose of this study is to determine what doses of anti-HIV medications are appropriate for pregnant women. Anti-HIV medication taken during pregnancy may control a woman's viral load and reduce the chance that the baby will become infected with HIV. Pregnant women may require different doses of anti-HIV drugs than women who are not pregnant. This study will use pharmacokinetic (PK) sampling to determine what doses of anti-HIV medications are best for HIV infected pregnant women and their infants. |
||||
Detailed Description | Pregnant women experience unique physiological changes that may result in clinically significant alterations in drug PKs. Unfortunately, there have been few clinical trials to study the PK of antiretroviral (ARV) medications in pregnant women. The development of appropriate dosing regimens for the HIV infected pregnant woman is critical to the health of both mother and fetus. Overdosing may lead to maternal adverse events and increased risk of fetal toxicity, while underdosing may lead to inadequate virologic control, increased risk of developing drug resistance mutations, and a higher rate of perinatal HIV transmission. This study will develop and evaluate dosing regimens that are most effective in preventing perinatal HIV transmission and in maintaining the health of both mother and fetus. Participants will be enrolled in this study starting from their twentieth week of pregnancy and for 12 weeks after delivery. Participants will not receive ARV medications through this study. Medical history, a physical exam, and blood and urine collection will occur during all study visits. Intensive PK sampling will be performed at study visits during the second and third trimester of pregnancy and between 2 and 3 weeks and 6 and 12 weeks postpartum. The timing of antepartum and postpartum PK samplings will vary by drug. Blood collection from the mother and the detached umbilical cord will occur during delivery. Additional study visits may occur depending on the ARV drug regimen prescribed. |
||||
Study Phase | |||||
Study Type † | Interventional | ||||
Study Design † | Treatment, Non-Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study | ||||
Condition † | HIV Infections | ||||
Intervention † | Procedure: Pharmacokinetic sampling | ||||
Study Arms / Comparison Groups | Experimental: Participants will be evaluated in order to determine the most effective dosing regimen in preventing perinatal HIV transmission. | ||||
Publications * |
|
||||
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status † | Recruiting | ||||
Estimated Enrollment † | 275 | ||||
Completion Date | |||||
Primary Completion Date | |||||
Eligibility Criteria † | Inclusion Criteria:
Exclusion Criteria:
|
||||
Gender | Female | ||||
Ages | |||||
Accepts Healthy Volunteers | No | ||||
Contacts †† |
|
||||
Location Countries † | United States, Puerto Rico | ||||
Expanded Access Status | |||||
Administrative Information | |||||
NCT ID † | NCT00042289 | ||||
Responsible Party | Rona Siskind, DAIDS | ||||
Secondary IDs †† | PACTG P1025 | ||||
Study Sponsor † | National Institute of Allergy and Infectious Diseases (NIAID) | ||||
Collaborators †† | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | ||||
Investigators † |
|
||||
Information Provided By | National Institute of Allergy and Infectious Diseases (NIAID) | ||||
Verification Date | February 2009 | ||||
† Required WHO trial registration data element. †† WHO trial registration data element that is required only if it exists. |